We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Gene Therapy Treatment Extends Life of Mice Severely Affected by Muscular Dystrophy

By LabMedica International staff writers
Posted on 11 Oct 2015
An alternative gene therapy approach was used to successfully treat a mouse model of Duchenne muscular dystrophy (DMD).

DMD is caused by mutations in the gene that encodes the protein dystrophin and the subsequent disruption of the dystrophin-associated protein complex (DAPC). More...
The disease effects about one of every 3,500 boys whose muscle function is so degraded that they die usually before they reach the age of 30.

To develop methods for treating this syndrome, investigators at Ohio State University (Columbus, USA) chose to work with mice deficient for dystrophin and utrophin, (mdx/utrn−/−) that die between six and 20 weeks of age because of severe muscle weakness, pronounced growth retardation, and kyphosis rather than the more frequently used dmx model whose animals are clinically normal despite lacking dystrophin.

Dystrophin deficiency has been definitively established as one of the root causes of the general class of myopathies collectively referred to as muscular dystrophy. In normal muscle cells, utrophin is located at the neuromuscular synapse and myotendinous junctions. It is necessary for normal membrane maintenance, and for the clustering of the acetylcholine receptor.

The investigators evaluated an alternative to dystrophin replacement by overexpressing the ITGA7 (integrin, alpha 7) gene using adeno-associated virus (AAV) delivery. ITGA7 is a laminin receptor in skeletal muscle that, like the dystrophin–glycoprotein complex, links the extracellular matrix to the internal actin cytoskeleton. ITGA7 is expressed in DMD patients and its overexpression does not elicit an immune response.

In the current study, five to seven day-old mice deficient for dystrophin and utrophin, (mdx/utrn−/−)were treated with the ITGA7 gene delivered via the AAV carrier. Results published in the August 11, 2015, online edition of the journal Human Gene Therapy revealed that by eight weeks following ITGA7 injection, there was widespread expression of the gene at the sarcolemma of multiple muscles. The increased expression of ITGA7 significantly extended longevity and reduced common features of the mdx/utrn−/− mouse, including kyphosis. Overexpression of alpha7 expression protected against loss of force following contraction-induced damage, and increased specific force in the diaphragm and EDL (extensor digitorum longus) muscles eight weeks after gene transfer.

Mice of the mdx/utrn−/− line usually die between six to 20 weeks of age, but gene transfer of alpha7 extended longevity by more than 10 weeks.

Related Links:

Ohio State University



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Clinical Informatics Platform
CLARION™
New
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.